← All trials
NCT06877351
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 14, 2024
- Primary completion
- Jan 1, 2027
- Completion date
- Jun 1, 2027
- First posted
- Mar 14, 2025
- Last posted
- Mar 14, 2025
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Buenos AiresLead sponsor
- University of Buenos AiresSponsor investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.